Christian Gisselbrecht
克里斯蒂安·吉塞尔布雷希特
MD
Professor Emeritus of Hematology; Senior Consultant, Lymphoma Unit血液学荣誉教授；淋巴瘤科高级顾问
👥Biography 个人简介
Christian Gisselbrecht, MD is Professor Emeritus of Hematology at Hôpital Saint-Louis, Paris. He is the architect of the CORAL trial, the largest prospective study of salvage chemotherapy in relapsed/refractory DLBCL, which defined ICE and DHAP as equivalent salvage backbones and delineated outcomes predictors.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
CORAL Trial — Salvage Therapy in DLBCL
Designed and led CORAL, the landmark international phase III trial comparing R-ICE vs R-DHAP in relapsed DLBCL, identifying IPI, prior rituximab, and early relapse as outcome predictors.
Autologous Transplant Consolidation in DLBCL
Established evidence base for high-dose therapy and autologous stem cell transplant consolidation in chemosensitive relapsed DLBCL, informing European and global practice guidelines.
Representative Works 代表性著作
Salvage Regimens with Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the CORAL Study
Journal of Clinical Oncology (2010)
Pivotal phase III study comparing R-ICE vs R-DHAP salvage plus ASCT in relapsed DLBCL, defining contemporary second-line treatment standards.
Prognostic factors for second-line therapy in patients with relapsed DLBCL: CORAL long-term analysis
Blood (2012)
Long-term analysis identifying early relapse and prior rituximab as negative predictors in salvage-transplant strategy for relapsed DLBCL.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 克里斯蒂安·吉塞尔布雷希特 的研究动态
Follow Christian Gisselbrecht's research updates
留下邮箱，当我们发布与 Christian Gisselbrecht（Hôpital Saint-Louis, AP-HP）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment